<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Agostino</forename><surname>Virdis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chiara</forename><surname>Tani</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Emiliano</forename><surname>Duranti</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabrina</forename><surname>Vagnani</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Linda</forename><surname>Carli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><forename type="middle">A</forename><surname>Kühl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Solini</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chiara</forename><surname>Baldini</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosaria</forename><surname>Talarico</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefano</forename><surname>Bombardieri</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefano</forename><surname>Taddei</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Marta</forename><surname>Mosca</surname></persName>
							<email>marta.mosca@med.unipi.it</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Rheumatology Unit</orgName>
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<addrLine>Via Roma, 67</addrLine>
									<postCode>56100</postCode>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">F32DE07B9230CF4463F654F2955BB78F</idno>
					<idno type="DOI">10.1186/s13075-015-0790-3</idno>
					<note type="submission">Received: 23 March 2015 Accepted: 17 September 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Introduction: Accelerated atherosclerosis is one of the major causes of morbidity in patients with systemic lupus erythematosus (SLE).</s><s>Endothelial dysfunction (ED) is considered an early marker of atherosclerosis.</s><s>It is a reversible alteration, thus representing an attractive target for prevention strategies against cardiovascular disease.</s><s>Studies have shown that ED occurs in patients with SLE even in the absence of severe, active disease.</s><s>Hydroxychloroquine (HCQ) is widely used in SLE to control disease activity, but its use is also associated with an improvement in long-term prognosis.</s><s>Beyond the beneficial effect in well-established disease, our hypothesis is that treatment with HCQ might have a beneficial impact on ED prevention in SLE.</s><s>The aim of this study was to assess the impact of early treatment with HCQ on ED in a murine model of SLE.</s><s>Methods: Twelve-week-old NZB/W F1 (NZ) and C57BL/6 J mice (controls) were allocated to receive HCQ or vehicle for 6, 12, or 18 weeks.</s><s>Proteinuria and anti-double-stranded DNA autoantibodies were determined.</s><s>ED was assessed in mesenteric arteries (pressurized myography).</s><s>Nitric oxide (NO) availability and reactive oxygen species (ROS) production were evaluated.</s><s>Vascular ROS production was measured with dihydroethidium (DHE) fluorescent dye.</s><s>Results: Starting from 18 weeks of age, NZ mice showed a progressive reduction in NO availability, which was normalized by ascorbic acid and apocynin in the up to 24-week-old group, and partly ameliorated in older animals.</s><s>HCQ administration normalized the NO availability in the up to 24-week-old group, with a partial amelioration in the 30-week-old group.</s><s>DHE analysis revealed a progressive increment of vascular ROS generation among NZ groups, which was prevented by apocynin.</s><s>Similarly, in the NZ HCQ-treated group, vascular ROS production was abrogated.</s><s>Conclusions: The ED that characterizes this mouse model of SLE is caused by the nicotinamide adenine dinucleotide phosphate oxidase-driven ROS excess.</s><s>Very early treatment with HCQ is able to exert vascular protection via an antioxidant effect.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>In recent years, the survival of patients with systemic lupus erythematosus (SLE) has increased substantially.</s><s>Reasons for the improved prognosis include earlier diagnosis, enhanced recognition of milder forms, and mindful use of treatments such as glucocorticoids and immunosuppressive agents.</s><s>However, because of prolonged life expectancy, patients with SLE are now exposed to an increased risk of morbidity related to the sequelae of disease activity, side effects of medications, and comorbid conditions, such as premature cardiovascular (CV) morbidity <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s></p><p><s>Accelerated atherosclerosis is one of the major causes of CV morbidity and mortality in patients with SLE.</s><s>Of note, over the past 3 decades, mortality has been significantly reduced for all causes among patients with SLE, with the exception of CV disease.</s><s>For these reasons, the prevention of long-term CV complications in patients with SLE, while still an unsolved issue, represents a particularly attractive target for intervention.</s><s>Beyond the concomitance with traditional CV risk factors, including obesity, hypertension, dyslipidemia, and diabetes mellitus, SLE is considered per se responsible for direct detrimental effects on the vasculature, which makes SLE itself a potent, independent CV risk factor <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s></p><p><s>Endothelial dysfunction (ED) is characterized by impaired nitric oxide (NO) availability and a concomitant increased reactive oxygen species (ROS) generation <ref type="bibr" target="#b4">[5]</ref>.</s><s>Such a systemic condition is shared by the majority of CV risk factors, is recognized as an early and major promoter for atherosclerosis and thrombosis, and is independently related to CV events <ref type="bibr" target="#b4">[5]</ref>.</s><s>Interestingly, SLE and atherosclerosis share mechanisms such as vascular inflammation, ROS excess, immune complexes, and complement activation, which are all able to elicit ED.</s><s>Of note, ED is a reversible alteration, thus representing a potentially attractive target for preventive intervention against CV disease.</s></p><p><s>Hydroxychloroquine (HCQ) is an antimalarial compound with immunomodulatory properties widely used in SLE owing to its multiple beneficial effects, including control of disease activity, reduction of damage accrual, improvement of survival, and a relatively safe profile <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref>.</s><s>In recent years, HCQ therapy has been associated with an improvement of CV prognosis in SLE.</s><s>A positive effect on traditional CV risk factors and on thrombotic risk has been described in SLE <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>; moreover, a beneficial effect on vascular reactivity indices has also been reported <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>.</s></p><p><s>However, it is still unclear whether the protective CV effect of antimalarials is the indirect result of better control of disease activity or, alternatively, a direct effect of HCQ on the endothelial microenvironment.</s><s>The availability of lupus murine models offers a great opportunity to study this relationship in a "simplified" setting to improve understanding of the role of the multiple contributing factors.</s></p><p><s>Recently, Gómez-Guzmán et al. <ref type="bibr" target="#b16">[17]</ref> have shown that short-term treatment with HCQ started at a late disease stage is able to reverse ED at the level of large arteries in a murine model of SLE, an effect mediated by a reduction of the nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase activity, which is a major ROS source.</s><s>Beyond the beneficial effect of the antimalarial in conditions of well-established disease, early HCQ use has been also associated with delayed SLE onset in humans <ref type="bibr" target="#b17">[18]</ref>.</s></p><p><s>We hypothesized that treatment with HCQ before the onset of the full-blown disease might delay or even prevent SLE-associated ED.</s><s>The present study was designed to assess the effect of HCQ on endothelial function in a murine model of SLE and its underlying mechanism.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animal treatment</head><p><s>All experiments were carried out in accordance with European Union Council Directive 2010/63/EU.</s><s>Female NZB/W F1 (NZ) mice and C57BL/6 J mice (controls; Ctrl) were obtained from Harlan Laboratories (Correzzana, Italy) and housed in a specific pathogen-free barrier facility.</s><s>Starting from 12 weeks of age, the animals were randomly allocated to receive HCQ (3 mg/kg/day) or vehicle (sham) in the drinking water.</s><s>The animals were divided into four groups: untreated control (Ctrl; n = 15), NZB/W F1 mice with untreated SLE (NZ; n = 30), control treated with HCQ (Ctrl-HCQ; n = 30), and NZB/W F1 mice with SLE treated with HCQ (NZ-HCQ, N = 30).</s><s>The mice were treated for three different periods (6, 12, or 18 weeks) (Table <ref type="table">1</ref>).</s><s>At the end of treatment, they were killed while under avertin-induced anesthesia.</s><s>The protocol was approved by the local University of Pisa ethics committee on use and care of animals.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serum and urinary assays</head><p><s>At the time the mice were killed, blood samples were collected and immediately placed in heparinized tubes.</s><s>Serum was separated by centrifugation and stored at −70 °C.</s><s>Serum titers of anti-double-stranded DNA (anti-dsDNA) autoantibodies were analyzed with a commercial enzyme-linked immunosorbent assay kit (Alpha Diagnostic International, San Antonio, TX, USA), 24-h urinary protein excretion was collected in metabolic cages and measured by dipstick analysis (Bayer, Leverkusen, Germany).</s><s>For both serum and urine assays, the person who performed the measurements was blinded to the age and treatment allocation of the mice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histopathology</head><p><s>The kidneys were excised, fixed overnight in 4 % formalin, and embedded in paraffin.</s><s>Sections (1-2 μm) were cut, dewaxed, and stained with hematoxylin and eosin (H&amp;E) and periodic acid-Schiff (PAS).</s><s>H&amp;E-and PAS-stained sections were evaluated for nephritis according to a modified score described by Tao et al. as follows <ref type="bibr" target="#b18">[19]</ref>: The nephritis score is the sum of the individual scores ranging from 0 to 12.</s><s>The images were acquired using an Axio Imager Z1 microscope (Carl Zeiss MicroImaging, Jena, Germany).</s><s>All evaluations were performed in a blinded manner.</s></p><formula xml:id="formula_0">Glomerulonephritis: 1,</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of small mesenteric arteries and functional experiments</head><p><s>A second-order branch of the mesenteric arterial tree was dissected and mounted on two-glass microcannulae in a pressurized myograph (model 110P; Danish Myo Technology, Aarhus, Denmark) as previously described <ref type="bibr" target="#b19">[20]</ref>.</s><s>Media and lumen dimensions were measured with the intraluminal pressure maintained at 45 mmHg.</s></p><p><s>Endothelium-dependent and -independent relaxations were assessed by measuring the dilatory responses of mesenteric arteries to cumulative concentrations of acetylcholine (ACh, 0.001-100 μM; Sigma-Aldrich, St. Louis, MO, USA) and sodium nitroprusside (SNP, 0.01-100 μΜ; Sigma-Aldrich).</s><s>Vessels were precontracted with norepinephrine (10 μM; Sigma-Aldrich).</s><s>This concentration was determined in dose titration experiments to establish the threshold concentration able to elicit similar contractions among the experimental groups.</s><s>To evaluate NO availability and ROS production, ACh concentration-response curves were constructed before and after 30-minute preincubation with the NOS inhibitor N ω -nitro-L-arginine methyl ester (L-NAME, 100 μM; Sigma-Aldrich) or the antioxidant ascorbic acid (10 mM, 30-minute preincubation; Sigma-Aldrich).</s><s>To evaluate whether oxidative stress could influence NO availability, an additional ACh curve was constructed for simultaneous incubation with L-NAME and ascorbic acid.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Involvement of NAD(P)H oxidase in endothelium-dependent relaxation</head><p><s>To ascertain the contribution of NAD(P)H oxidase to ED in additional experiments on NZ vessels (n = 6 each group), an ACh curve was constructed after 30-minute incubation with two different NAD(P)H oxidase inhibitors, apocynin (Apo, 10 μM; Fluka-Sigma-Aldrich, St. Gallen, Switzerland) and diphenyleneiodinium (DPI, 10 μM; Sigma-Aldrich) <ref type="bibr" target="#b20">[21]</ref>.</s><s>To assess the possibility that NAD(P)H oxidase could affect NO availability, Ach was infused under simultaneous incubation with L-NAME and Apo or DPI.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Detection of vascular superoxide anion generation</head><p><s>The in situ production of superoxide anion was measured by means of the fluorescent dye dihydroethidium (DHE; Sigma-Aldrich) as previously described <ref type="bibr" target="#b21">[22]</ref>.</s><s>Each segment was analyzed simultaneously after incubation with Apo (100 μM) or Krebs solution.</s><s>Additional incubations with the superoxide scavenger polyethylene glycol superoxide dismutase (PEG-SOD, 600 U ml −1 ; Sigma-Aldrich) were performed as technical positive controls.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis</head><p><s>Maximal ACh-and SNP-induced responses (E max ) were calculated as maximal percentage increments of lumen diameter.</s><s>The results are presented as mean ± SEM.</s><s>The statistical significance of relaxation responses was assessed, taking into consideration the time course and treatment by two-way analysis of variance (ANOVA).</s><s>Other comparisons were made by repeated-measures ANOVA or by one-way ANOVA followed by a Student-Newman-Keuls test, where appropriate.</s><s>A value of P &lt; 0.05 was considered statistically significant.</s><s>The variable n indicates the number of experiments.</s><s>All analyses were performed using Prism version 5.0 software (GraphPad Software, La Jolla, CA, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal parameters Proteinuria</head><p><s>In the NZ group, the baseline (weeks 8-12) levels of 24-h urinary protein excretion was 0.154 ± 0.53 mg.</s><s>It started to increase at 18 weeks (mean 3.5 ± 2.7 mg; P = 0.04), and 40 % of animals had proteinuria ≥100 mg/dl.</s><s>Proteinuria remained stable during the following weeks (4.06 ± 2.8 mg at 24 weeks, 4.9 ± 2.2 mg at 30 weeks; P = ns) and increased at 36 weeks (12.5 ± 3 mg; P &gt; 0.001) (Table <ref type="table">1</ref>).</s></p><p><s>In the NZ-HCQ group, proteinuria was stable across 12-30 weeks of age, with no significant differences between baseline (0.22 ± 0.2 mg) and 30 weeks (0.35 ± 0.34 mg; P = ns); however, significantly higher levels of proteinuria were observed at 36 weeks (mean 12 ± 18 mg; P &lt; 0.001) (Table <ref type="table">1</ref>).</s></p><p><s>In control mice, proteinuria was stable across 12-40 weeks of age (mean 1.44 ± 4.1 mg) (Table <ref type="table">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Anti-dsDNA autoantibody titers</head><p><s>Anti-dsDNA antibodies were detectable starting at 12 weeks of age in NZ mice (33 % positivity); however, a significant increase in titers was observed thereafter, with higher serological activity (87 % positivity) at 24 weeks of age (47 % positivity at 18 weeks, 67 % at 30 weeks).</s><s>In the NZ-HCQ group, anti-dsDNA antibody positivity at 24 weeks of age was 20 %, significantly lower than that in the NZ mice (P = 0.002).</s><s>At 30 weeks of age, the anti-dsDNA positivity was 66 %, with no differences from age-matched, untreated mice.</s><s>Figure <ref type="figure" target="#fig_0">1</ref> shows the anti-dsDNA titers at different time points in NZ, NZ-HCQ, and Ctrl mice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nephritis score</head><p><s>Initial histopathological lesions suggestive of nephritis appeared on kidneys from NZ mice killed at 18 weeks of age, then, the degree of nephritis increased progressively until the last observation at age 36 weeks (mean score 2.75 ± 1.25).</s><s>Similar nephritis scores were observed in kidneys from NZ-HCQ mice at 24, 30, and 36 weeks of age.</s><s>These data are reported in Table <ref type="table" target="#tab_1">2</ref>.</s></p><p><s>No histopathological lesions suggestive of nephritis were detected in control mice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endothelium-dependent relaxation in Ctrl and SLE mice: role of NO availability and ROS production</head><p><s>In Ctrl animals, relaxation in response to ACh was preserved up to week 24 (E max ACh, 12 weeks: 99.7 ± 0.6 %; 18 weeks: 99.8 ± 0.4 %; 24 weeks: 99.6 ± 0.7 %), but it was attenuated at week 30 (90.0 ± 0.9 %) (Fig. <ref type="figure">2a</ref>).</s><s>L-NAME significantly blunted the relaxation in response to ACh at baseline and until 30 weeks, when a reduced inhibitory effect emerged (Fig. <ref type="figure">3</ref>).</s><s>Moreover, ascorbic acid was ineffective in changing the vascular response to ACh at baseline (E max ACh + ascorbic acid: 99.1 ± 0.4 %) and until 30 weeks (E max ACh + ascorbic acid, 12 weeks: 98.2 ± 0.7 %; 24 weeks: 98.4 ± 0.9 %; 30 weeks: 98.3 ± 0.6 %), when it normalized the relaxation response to ACh (E max ACh + ascorbic acid: 96.9 ± 0.4 %) and restored the inhibitory effect of L-NAME on ACh (54.8 ± 0.9 %).</s></p><p><s>In NZ mice, relaxation in response to ACh, though preserved at baseline (12 weeks: 99.8 ± 0.4 %), was significantly reduced at week 18 (87.9</s><s>± 1.1 %; P &lt; 0.05 vs. Ctrl), with further progressive decline by week 24 (72.3 ± 1.2 %; P &lt; 0.01 vs. Ctrl) and week 30 (62.0 ± 0.6 %; P &lt; 0.01 vs. Ctrl) (Fig. <ref type="figure">2b</ref>).</s><s>The inhibition of L-NAME on ACh was preserved at baseline (Fig. <ref type="figure">3</ref>) but started to decline at 18 weeks, with a progressive decrement at 24 and 30 weeks, at which point the response to ACh was virtually resistant to L-NAME (Fig. <ref type="figure">2</ref>).</s><s>Ascorbic acid normalized the relaxation in response to ACh in all groups (E max Ach + ascorbic acid, 18 weeks: 94.0 ± 1.2 %; 24 weeks: 93.5 ± 1.2 %; 30 weeks: 95.3 ± 0.6 %; P = N.S. vs. baseline) and restored the inhibitory effect of L-NAME on ACh (18 weeks: 52.7 ± 2.4 %; 24 weeks: 50.9 ± 2.1 %; 30 weeks: 53.6 ± 2.9 %).</s><s>Relaxation in response to SNP started to decline at week 30 among Ctrl mice (decrement above baseline −10.3 ± 1.1 %; P &lt; 0.05).</s><s>A significant decrement of vascular response to SNP at week 30 was also evident in the SLE group (decrement above baseline −24.3 ± 1.4 %; P &lt; 0.001), with a greater reduction (P &lt; 0.05) compared with the age-matched Ctrl group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of HCQ on vascular reactivity</head><p><s>Among NZ-HCQ mice, in the 18-week and 24-week subgroups, HCQ administration normalized the relaxation in response to ACh (Fig. <ref type="figure">2c</ref>) and restored the inhibition by L-NAME on ACh (Fig. <ref type="figure">3</ref>).</s><s>In older NZ animals, HCQ potentiated, without normalizing, the relaxation in response to ACh and partly restored the L-NAME effect on</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Involvement of NAD(P)H oxidase in endothelium-dependent relaxation</head><p><s>In the Ctrl group, the relaxation in response to ACh was not modified by Apo at any time point (Additional file 1).</s><s>In contrast, in the NZ group, Apo, while ineffective at baseline, normalized the response to ACh at 18 and 24 weeks (Additional file 2) and restored the inhibitory effect of L-NAME on ACh (Fig. <ref type="figure">3</ref>).</s><s>Of note, at 30 weeks, Apo improved the relaxation in response to ACh (Additional file 2), although it did not normalize it, and partly ameliorated the inhibitory effect of L-NAME on the endothelial agonist (Fig. <ref type="figure">3</ref>).</s><s>Similar results were obtained with DPI, which normalized the vascular response to ACh in NZ mice at 18 and 24 weeks and restored the inhibitory effect of L-NAME on ACh (Additional file 3).</s><s>At 30 weeks, DPI only in part potentiated the response to ACh and the inhibition by L-NAME (Additional file 3).</s></p><p><s>In the NZ-HCQ groups, Apo incubation was devoid of any effect, at any time, either on the response to ACh or on the inhibition by L-NAME (Fig. <ref type="figure">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DHE analysis of vascular superoxide anion generation</head><p><s>At baseline, DHE red fluorescence revealed a weak and similar mesenteric superoxide anion production among the Ctrl and NZ groups (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>In the Ctrl group, advancing age failed to elicit any significant increment of superoxide generation.</s><s>In contrast, in NZ mice, a dramatic increment of superoxide anion production was already present in the 18-week group, with a progressive production at week 24 and a further generation at 30 weeks (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>Incubation with Apo prevented the superoxide production at any time point (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>Likewise, in the NZ-HCQ group, superoxide production was completely abrogated (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>As technical positive controls, in vessels from NZ mice incubated with PEG-SOD, the superoxide generation was completely abolished (Fig. <ref type="figure" target="#fig_2">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the present study, we have shown that the early administration of HCQ is able to prevent the development of ED in a murine model of SLE.</s></p><p><s>Endothelial function impairment has been described previously in mice as well as in human SLE <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>.</s><s>In our mouse model, ED occurred at a very early stage of the disease in the absence of overt disease activity.</s><s>As early as 18 weeks of age, mesenteric small arteries from the NZ group already showed a blunted endotheliumdependent relaxation, together with a reduced inhibitory effect of L-NAME on ACh, and at this stage anti-dsDNA antibodies were positive, and only initial urinary abnormalities were detectable in some mice.</s><s>DHE analysis revealed a dramatic increment of vascular superoxide anion generation.</s></p><p><s>To exclude that these effects might be caused by ageing per se, a well-recognized major contributor to vascular functional changes <ref type="bibr" target="#b30">[31]</ref>, the results from each time of exposure to the disease were compared with data obtained in age-related control groups.</s><s>Indeed, vessels from control mice showed a preserved inhibitory effect of L-NAME on endothelium-dependent relaxation and no evidence of ROS generation up to 30 weeks.</s><s>At this age, the control group displayed a reduced NO availability, but this reduction was less pronounced than in the NZ group, without any increased ROS production.</s><s>Therefore, these data indicate that SLE-associated ED is a functional vascular alteration occurring early in the disease course, regardless of disease activity and aging.</s><s>These observations fully support the observation made in patients with SLE who might experience premature atherosclerosis independently of traditional risk factors for CV disease <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b31">32]</ref>.</s></p><p><s>In our model, early and long-term HCQ administration, though ineffective in modulating endothelial function in control mice, normalized the endothelium-dependent relaxation and the inhibitory effect of L-NAME on ACh as well, in both 8-week-old and 24-week-old NZ mice.</s><s>This protective effect, although still evident, was only partially effective in NZ at 30 weeks of age.</s></p><p><s>It is well known that renal involvement itself can cause ED.</s><s>Thus, the observed beneficial effect of HCQ on endothelial function might be consequent to an improvement of kidney disease <ref type="bibr" target="#b32">[33]</ref>.</s><s>However, in our experimental model, this is an unlikely hypothesis, considering that the reversal of ED induced by HCQ occurred before the occurrence of overt kidney disease.</s><s>In addition, even if chronic administration of HCQ has a positive effect on proteinuria and anti-dsDNA autoantibodies, histological analysis revealed a comparable activity and damage scores in the kidneys from HCQ-treated and untreated mice.</s><s>In conjunction, these findings indicate that the protective vascular effects by HCQ were not exclusively related to kidney disease and suggest the ability of the drug to interfere with the vascular inflammatory process and the immunological mechanisms accounting for ED, as previously demonstrated <ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref>.</s></p><p><s>Apo, an NAD(P)H oxidase inhibitor, normalized the inhibitory effect of L-NAME on ACh-induced relaxation up to 30 weeks of age.</s><s>Moreover, DHE staining showed that Apo prevented the SLE-induced vascular ROS at any time point of the disease.</s></p><p><s>On the basis of these findings, it is conceivable that NAD(P)H oxidase is a major enzymatic pathway that mediates vascular ROS production in this model of SLE, a process that likely initiates at a very early stage of the disease.</s></p><p><s>Indeed, the present data extend the previous demonstration of the beneficial effect of HCQ on large arteries <ref type="bibr" target="#b16">[17]</ref> to the peripheral microcirculation and demonstrate a property of this compound of delaying the onset of vascular functional alterations for a long period.</s></p><p><s>The main novelty of the data relies on the fact that our work offers a different perspective, given that early disease is the main focus of the study.</s><s>Representative DHE staining (upper panels) and quantitative analysis of the red signal (lower panels; original magnification, ×40) in mesenteric arteries from C57BL/6 J mice control mice (Ctrl) and NZB/W F1 mice (NZ) at baseline, from NZ groups without or with apocynin (Apo) or polyethylene glycol superoxide dismutase (PEG-SOD), and from NZB/W F1 mice treated with hydroxychloroquine (NZ-HCQ) at different time points.</s><s>Each column represents the mean ± SEM of six experiments.</s><s>*P &lt; 0.001; † P &lt; 0.05 Indeed, in 2010, Thacker et al. <ref type="bibr" target="#b22">[23]</ref> described an impaired endothelial-dependent vasorelaxation at the aortic level at 36 weeks of age in the same model, in concomitance with an overt disease expression.</s><s>However, in line with our observations, they also showed an earlier impairment in phenotype and function of endothelial progenitor cells, before full disease expression <ref type="bibr" target="#b22">[23]</ref>.</s></p><p><s>More recently, Gómez-Guzmán et al. <ref type="bibr" target="#b16">[17]</ref>, in the same SLE model, described the protective effect of a short course of HCQ on vascular parameters (hypertension, heart rate, cardiac hypertrophy) as well as on disease-related variables.</s><s>Similar to us, they found, even if in a large vessel bed such as the aorta, a beneficial effect of HCQ on endotheliumdependent vasodilation on vascular ROS levels and NADPH oxidase activity.</s><s>However, with respect to our study, the authors started the treatment in an advanced disease stage, after a long-standing autoimmune-mediated inflammatory process.</s><s>Thus, we can postulate that what we observed is not only the result of an immunological process but also a mixture of metabolism, purely CV detriment, and aging.</s><s>This is supported by the fact that the administration of a mixture of antioxidants yielded similar results <ref type="bibr" target="#b16">[17]</ref>.</s></p><p><s>Some limitations of this study have to be acknowledged.</s><s>First, we have histological data of the kidney from advanced disease, but no earlier evaluations (18-20 weeks of age) were available.</s><s>This aspect can account for some discrepancy observed between the proteinuria trend and the kidney histology between treated and untreated mice.</s><s>Indeed, whereas a delay in proteinuria occurrence has been observed in mice during HCQ treatment, this effect was not reflected by the later histology scores.</s><s>Second, no serial data on anti-dsDNA antibody activity were available from each mouse, because blood samples were taken only at the time they were killed.</s><s>This could reduce the accuracy in defining disease progression.</s><s>Moreover, the mice were given the HCQ in their drinking water; although this is a common practice, variations in individual mice as to intake cannot be excluded.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Anti-double-stranded DNA (anti-dsDNA) levels at different time points.</s><s>The results are expressed as optical density (OD) (mean of the OD readings of serum at 450 nm) as measured using a microtiter plate reader (Ultrospec 2000; Amersham Pharmacia Biotech, Little Chalfont, UK).</s><s>*P = 0.02 in NZB/W F1 mice treated with hydroxychloroquine (NZ-HCQ) vs. NZB/W F1 (NZ) mice at 24 weeks</s></p></div></figDesc><graphic coords="4,66.16,528.95,214.99,135.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 Fig. 3</head><label>23</label><figDesc><div><p><s>Fig. 2 Relaxations in response to acetylcholine in mesenteric arteries at baseline and different time points in control mice (a), NZB/W F1 mice (NZ) (b) or NZB/W F1 mice treated with hydroxychloroquine (NZ-HCQ) (c).</s><s>Each point represents the mean ± SEM of eight experiments.</s><s>*P &lt; 0.05; † P &lt; 0.01</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 4</head><label>4</label><figDesc><div><p><s>Fig.4Dihydroethidium (DHE) staining for detection of superoxide production.</s><s>Representative DHE staining (upper panels) and quantitative analysis of the red signal (lower panels; original magnification, ×40) in mesenteric arteries from C57BL/6 J mice control mice (Ctrl) and NZB/W F1 mice (NZ) at baseline, from NZ groups without or with apocynin (Apo) or polyethylene glycol superoxide dismutase (PEG-SOD), and from NZB/W F1 mice treated with hydroxychloroquine (NZ-HCQ) at different time points.</s><s>Each column represents the mean ± SEM of six experiments.</s><s>*P &lt; 0.001; † P &lt; 0.05</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 Histopathology</head><label>2</label><figDesc><div><p><s>.s. not significant, NZ NZB/W F1 mice, NZ-HCQ NZB/W F1 mice treated with hydroxychloroquine, SD standard deviation</s></p></div></figDesc><table><row><cell>Age, wk</cell><cell cols="2">Nephritis score (mean ± SD)</cell><cell>P value</cell></row><row><cell></cell><cell>NZ</cell><cell>NZ-HCQ</cell><cell></cell></row><row><cell>12</cell><cell>0 ± 0</cell><cell>-</cell><cell>n.s.</cell></row><row><cell>18</cell><cell>0.4 ± 0.5</cell><cell>-</cell><cell>n.s.</cell></row><row><cell>24</cell><cell>0.75 ± 0.5</cell><cell>2 ± 0.5</cell><cell>n.s.</cell></row><row><cell>30</cell><cell>1 ± 0.9</cell><cell>2 ± 0.5</cell><cell>n.s.</cell></row><row><cell>36</cell><cell>2.8 ± 1.2</cell><cell>3 ± 4.6</cell><cell>n.s.</cell></row></table><note><p><s>n</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors thank Dr. Simone Spieckermann (Universitätsmedizin Berlin) for technical assistance and Dr. Wendy Doherty for English language editing of the manuscript.</s></p><p><s>Author details 1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. <ref type="bibr" target="#b1">2</ref> Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. <ref type="bibr" target="#b2">3</ref> GenOMeC PhD, University of Siena, Siena, Italy. <ref type="bibr" target="#b3">4</ref> Medical Clinic I for Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité -Universitätsmedizin Berlin, Hindenburgdamm 30, D-12203 Berlin, Germany.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>This study shows that early treatment with HCQ is able to reduce early ED related to the inflammatory process in a mouse model of SLE.</s><s>These data may support the clinical observations of the potential beneficial effect of HCQ in preventing vascular damage in human SLE and may support the early introduction of HCQ in patients with recent disease onset.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p><s>Additional file 1: Supplemental methods and results.</s><s>Methods: preparation, mounting and measurements in small arteries and detection of vascular superoxide anion generation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>AV and CT designed the study, analyzed the data, and drafted the manuscript.</s><s>ED carried out the endothelial function analysis and helped to draft the manuscript.</s><s>SV and LC took care of the animals, performed urinary and blood sample analyses, and helped to draft the manuscript.</s><s>AAK carried out the kidney histopathology and revised the manuscript.</s><s>AS carried out the DHE and gene expression analyses and revised the manuscript.</s><s>RT and CB participated in study design and coordination and helped to draft the manuscript.</s><s>MM, SB, and ST conceived of the study and extensively edited the manuscript.</s><s>All authors read and approved the final manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">An update on mortality in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ippolito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Petri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="S72" to="79" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Schoenfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kasturi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Costenbader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="77" to="95" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Esdaile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abrahamowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Grodzicky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Panaritis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Berger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="2331" to="2337" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Roman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Shanker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Lockshin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sammaritano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Simantov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page" from="2399" to="2406" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The assessment of endothelial function: from research into clinical practice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Flammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Celermajer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Creager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Deanfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ganz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="753" to="767" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ruiz-Irastorza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ramos-Casals</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brito-Zeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Khamashta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="20" to="28" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Fessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Alarcón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mcgwin</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roseman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bastian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1473" to="1480" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Akhavan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Gladman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Urowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Fortin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="831" to="841" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Pons-Estel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Alarcón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Vilá</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Reveille</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="393" to="400" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort</title>
		<author>
			<persName><forename type="first">R</forename><surname>Willis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Seif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mcgwin</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Martinez-Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lupus</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="830" to="835" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Metzger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Stecher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Kern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="322" to="326" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Petri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lakatta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Magder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="254" to="259" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Borba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bonfá</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="780" to="785" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome</title>
		<author>
			<persName><forename type="first">C</forename><surname>Belizna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autoimmun Rev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="358" to="362" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Vascular stiffness in women with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">F</forename><surname>Selzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sutton-Tyrrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tracy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Manzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1075" to="1082" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tanay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leibovitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frayman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zimlichman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shargorodsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gavish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1108</biblScope>
			<biblScope unit="page" from="24" to="34" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gómez-Guzmán</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jiménez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sánchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Zarzuelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gómez-Morales</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="330" to="337" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">R</forename><surname>Kim-Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Bruner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Mcclain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Arbuckle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lupus</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="401" to="409" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice</title>
		<author>
			<persName><forename type="first">X</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Longo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Lipsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">R24</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of iNOS and oxidative stress</title>
		<author>
			<persName><forename type="first">A</forename><surname>Virdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Colucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fornai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blandizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Duranti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pinto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope unit="page" from="945" to="953" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Paravicini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Touyz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="S170" to="S180" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Virdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Santini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Colucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Duranti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salvetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rugani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="238" to="247" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Duquaine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lupus</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="288" to="299" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Mclemore</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Regul Integr Comp Physiol</title>
		<imprint>
			<biblScope unit="volume">292</biblScope>
			<biblScope unit="page" from="R736" to="742" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">High dietary fat promotes visceral obesity and impaired endothelial function in female mice with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gend Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="150" to="155" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vivekanandan-Giri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="2975" to="2985" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Prognostic value of flow mediated dilation in patients with systemic lupus erythematosus: a pilot prospective cohort study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ghiadoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Armenia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Raimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Plantinga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">236</biblScope>
			<biblScope unit="page" from="381" to="384" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Clinical and methodological aspects of endothelial function in patients with systemic autoimmune diseases</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ghiadoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mosca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Virdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taddei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bombardieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="680" to="687" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Endothelial function and arterial stiffness assessment as early surrogate markers of vascular risk in patients with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Chin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thumboo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="295" to="301" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: a metaanalysis and metaregression</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1296" to="1303" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Age-related reduction of nitric oxide availability and oxidative stress in humans</title>
		<author>
			<persName><forename type="first">S</forename><surname>Taddei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Virdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ghiadoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salvetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bernini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Magagna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="274" to="279" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Not only … but also&apos;: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Bruce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1492" to="1502" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Endothelial dysfunction and oxidative stress in chronic renal failure</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ghiadoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cupisti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mattei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cardinal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Favilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nephrol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="512" to="519" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">New insights into mechanisms of therapeutic effects of antimalarial agents in SLE</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Gudsoorkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Weisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Venuturupalli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Rheumatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="522" to="533" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Hydroxylchloroquine use is associated with decreased soluble TNF receptor levels in SLE patient samples</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Przebinda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Munroe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Guthridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Merrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>James</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>abstract 1922</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="S845" to="846" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Hydroxychloroquine is associated with impaired interferon-α and tumor necrosis factor-α production by plasmacytoid dendritic cells in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sacre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Criswell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mccune</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">R155</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α, interleukin 6, and interferon-γ production by peripheral blood mononuclear cells</title>
		<author>
			<persName><surname>Van Den Borne</surname></persName>
		</author>
		<author>
			<persName><surname>Be</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Dijkmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>De Rooij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Le Cessie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Verweij</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="55" to="60" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
